Clinical trials: Severe Pneumonia
SARS CoV 2 Infection
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.
- Trial name
- ICASARS (NCT05407597)
- Testing
- Icatibant, 0.9% Sodium Chloride Injection
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Belfast Health and Social Care Trust
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Two Fixed Dose Combinations of Aclidinium Bromide With Formoterol Fumarate
The purpose of this multicenter, dose-ranging study is to compare two Fixed-Dose Combinations of aclidinium bromide and formoterol fumarate with placebo, aclidinium bromide and formoterol fumarate, all administered BID in…
- Trial name
- ALIGHT-COPD (NCT01078623)
- Testing
- Aclidinium 200 μg / formoterol 12 μg, Formoterol 12 μg, Aclidinium 200 μg
- Where
- 10 sites in Czechia, Romania
- Volunteers
- 176 people
- Sponsor
- AstraZeneca
Stem Cell Transplant Complications
KIR Sequencing and Typing for Allograft in Nancy
The use of haploidentical donors for aHSCT has greatly increased this past decade leading to a major paradigm shift: while finding 10/10 HLA-matched donors represented the prior difficulty for decades, the current problem is…
- Trial name
- KIR-STAN (NCT04882605)
- Testing
- MHC typing, KIR typing, Assessment of KIR-based prediction scores
- Volunteers
- 156 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19, Stress Disorders, Post-Traumatic
Psychological Impact of Medical Evacuations on Families of Patients Admitted to Intensive Care Unit for Severe COVID-19
At the "Métropole Savoie" hospital, to deal with the daily influx of severe patients during the second wave of COVID-19, 23 patients had to be transferred away from their home city and far from their families as part of a medical…
- Trial name
- IPES-CoV (NCT05421182)
- Testing
- Revised Impact of Event Scale, Hospital Anxiety and Depression scale, 36-Item Short Form Survey
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
Critical Confirmed Coronavirus Disease (COVID)-19
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
The purpose of this study is to evaluate the clinical response of sirukumab (administered as a single intravenous dose) plus standard of care (SOC) compared to placebo plus SOC in COVID-19.
- Trial name
- NCT04380961
- Testing
- Sirukumab, Standard of Care (SOC)
- Where
- 16 sites in United States
- Volunteers
- 212 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Myasthenia Gravis
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection
Coronavirus disease 2019 (COVID-19), declared by the World Health Organization (WHO) as a "public health emergency of international concern" (January 31, 2020), has posed a significant threat to global health.
- Trial name
- CO-MY-COVID (NCT04695379)
- Where
- 10 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Bordeaux
COVID-19 Pneumonia
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome.
- Trial name
- NCT04449588
- Testing
- BDB-001 Injection, Conventional treatment
- Where
- 12 sites in Bangladesh, China and 3 more
- Volunteers
- 369 people
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Covid19, SARS-CoV Infection
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
The main objective of this cohort is to characterize COVID-19 patients hospitalized in infectious disease department. The collection of clinical and biological data from start of hospitalization to long-term follow up will…
- Trial name
- NCT04779021
- Testing
- Hospitalisation for SARS-COV2 infection
- Where
- 2 sites in France
- Volunteers
- 1,300 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
Severe Community-acquired Pneumonia (sCAP)
Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)
Severe community-acquired pneumonia (sCAP) has a high mortality rate of 25-50%. Excessive host inflammatory responses contribute to poor outcomes.
- Trial name
- PANDA-SCAP (NCT07152587)
- Testing
- Low dose steroids, Moderate dose steroids, Saline (0.9% NaCl)
- Volunteers
- 1,500 people
- Sponsor
- Qingyuan Zhan
SARS-CoV 2, COVID-19
Assessment of the Psycho-social Impact of COVID-19 Outbreak
It has been shown in previous important outbreaks of infectious diseases that they have a huge impact on individuals and communities.
- Conditions
- SARS-CoV 2, COVID-19, Quality of Life, Mental Health Wellness 1
- Trial name
- COM-COVID (NCT04378452)
- Testing
- COM-COVID anonimous survey
- Where
- 4 sites in Spain
- Volunteers
- 56,656 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
Covid19, SARS-CoV Infection
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
Administration of Zinc and resveratrol or double placebo for a period of 5 days and will be monitored for a 14 day period in covid-19 positive patients in an outpatient setting
- Trial name
- Reszinate (NCT04542993)
- Testing
- Zinc Picolinate, Resveratrol
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Swedish Medical Center
COVID, Pneumonia, Viral
High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy
Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.
- Conditions
- COVID, Pneumonia, Viral, Coagulation Disorder
- Trial name
- COVID-19 HD (NCT04408235)
- Testing
- Enoxaparin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Pneumonia Childhood
Severe Pneumonia Diagnostic in Pediatric Population by Lung Ultrasonography and Procalcitonin
Lung ultrasound (LUS) in combination with a biomarker has not yet been studied. The investigators propose a clinical trial where the primary aims are: 1.
- Trial name
- PROLUSP (NCT04217980)
- Testing
- Lung ultrasonography (LUS) or Chest X ray (CXR)
- Where
- 2 sites in Spain
- Volunteers
- 202 people
- Sponsor
- Fundació Sant Joan de Déu
Covid19, SARS (Severe Acute Respiratory Syndrome)
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Coronavirus Disease 2019 (COVID-19) (previously called 2019-nCOV acute respiratory disease) is caused by SARS-CoV-2, a positive-sense single-stranded RNA virus of the coronavirus family.
- Trial name
- NCT04590274
- Testing
- Hydroxychloroquine, Vitamins and Minerals, Azithromycin
- Volunteers
- healthy volunteers welcome
- Sponsor
- International Brain Research Foundation
Covid19, Ventilators, Mechanical
Efficacy of FES Cycling After a Severe Form of COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease 2019 (COVID-19) affect at late march 2021 more than 127 millions of persons worldwide (including more than 4.5 millions in France…
- Conditions
- Covid19, Ventilators, Mechanical, Respiratory Distress Syndrome
- Trial name
- FESrehabCoV (NCT04841746)
- Testing
- Physical therapy that include a standardized cycling training with functional electrical stimulation, Physical therapy that include a standardized cycling training with no additional functional electrical stimulation
- Where
- France
- Volunteers
- 22 people
- Sponsor
- Hospices Civils de Lyon
Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID)
Evaluation of Patients With Immune Function Abnormalities
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
- Conditions
- Chronic Granulomatous Disease (CGD), X-Linked Severe Combined Immune Deficiency (XSCID), Leukocyte Adhesion Deficiency 1 (LAD), Graft Versus Host Disease (cGvHD)
- Trial name
- NCT00128973
- Where
- United States
- Volunteers
- 3,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Avium-Intracellulare Infection
A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections
This study will test the safety and effectiveness of inhaled interferon gamma-1b and oral antibiotics for treating mycobacterium avium complex (MAC) infection of the lungs.
- Trial name
- NCT00021567
- Testing
- Interferon Gamma for Aerosol
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pneumonia Childhood
A Feasibility Study Evaluating a Novel Mask (Nasal Reservoir Cannula)
This study evaluates the addition of a novel mask (nasal reservoir cannula) to a standard nasal cannula during supplemental oxygenation for the treatment of hospitalized pediatric patients with hypoxemia due to severe pneumonia.
- Trial name
- NCT03929484
- Testing
- Nasal reservoir cannula
- Where
- Uganda
- Volunteers
- 8 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.